New data confirm that Foradil (formoterol fumarate) improves quality of life of COPD patients

1. Poster 498: Formoterol dry powder improves the quality of life in patients with COPD whereas the effect of ipratropium bromide is similar to placebo. A.P.M.Greefhorst1, R.Dahl2, D.Nowak3, V. Nonikov4, C.Colacchio5, A.M.Byrne5; 1. Streekziekenhuis Midden Twente, Hengelo, The Netherlands; 2. Aarhus Kommunehospital, Denmark; 3. Klinika Pneumonologii I Elergologii, Lodz, Poland; 4. Central Clinical Hospital, Moscow, Russia; 5. Novartis Horsham Research Centre, United Kingdom.

2. Poster 499: Onset of action of inhaled formoterol compared to ipratropium bromide in patients with COPD. R.Dahl*, A.P.M.Greefhorstf, D.Nowakf, V.Nonikov, A.Byrne** and the Novartis Study Group on COPD. *Aarhus Kommunehospital, DK; fStreekziekenhuis Midden Twente, Hengelo, NL; fKlinika Pneumonologii I Elergologii, Lodz, PL; Central Clinical Hospital, Moscow, RUS; and **The Novartis Horsham Research Centre, GB.

3. Poster 497: The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD R.Dahl1, P.Kristufek2, A.P.M.Greefhorst3, T.R.Amgott4, G.Della Cioppa5, M.H.Thomson5; ‘Aarhus Kommunehospital, Denmark; 2National ТВ and Respiratory Disease Institute, Bratislava, Slovak Republic; 3Streekziekenhuis Midden Twente, Hengelo, The Netherlands; 4Pulmonary Associates, PA, Phoenix, Arizona; 5Novartis Horsham Research Centre, United Kingdom.

4. 1999 World Health Report. World Health Organization, 1999.